She envisages a society in which the medical and socioeconomic benefits of innovations in healthcare are valued according to their true worth – by making the Social Impact of health interventions visible. Alongside her Health Economics team, Dr. Müller enables stakeholders from politics and business to recognize the value of health to society, where gaps in healthcare exist, and which measures can effectively deliver better, more resilient health.
Dr. Malina Müller holds a PhD on the determinants of healthcare utilization in German social health insurance (SHI) and is a guest lecturer at various universities across Germany. She covers topics including Health Economic Decision Modelling, Labor Market and Alternative Economics, and Institutional Economics. Since joining the Health Economics team at WifOR in 2016, Dr. Müller has lead research projects analyzing the Social Impact of medical innovations and the long-term benefits of preventative approaches for populations at a macro level. Her research models the efficacy and return on investment (ROI) of innovative medicines using advanced econometrics, statistical methodologies, and simulations.
- Dr. rer. pol. (PhD) der Universität Koblenz-Landau
Thesis: Misdiagnosis homo economicus? The utilization of healthcare services in Germany and the role of co-payments
- Social Sciences (BA and MA) from the University of Koblenz-Landau (Germany)
- Health Economic Policy
- Alternative Economics
- Social Impact (SI) and Return on Investment (ROI) of medical interventions
- Statistical and simulation modelling
Project Partners and Clients
- Bundesverband der Deutschen Industrie e.V. (BDI)
- Deutscher Hausärzteverband e.V. (HÄV)
- Irish Pharmaceutical Healthcare Association (IPHA)
- Mexican Association of Pharmaceutical Research Industries, A.C. (AMIIF)
- German Federal Ministry for Education and Research (BMBF)
- Companies: Amgen, Boehringer Ingelheim, Celgene, Galapagos, Novartis, Pfizer, Portola Pharmaceuticals, Roche, Sanofi, Takeda, Vertex Pharmaceuticals